NDAORALTABLET, DELAYED RELEASE
Approved
Oct 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
EC-NAPROSYN (naproxen) by Hamilton medical is cyclooxygenase inhibitors [moa]. Approved for pain, osteoarthritis, rheumatoid arthritis and 2 more indications. First approved in 1994.
Drug data last refreshed Yesterday
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications (5)
Worked on EC-NAPROSYN at Hamilton medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.